Six Italian companies are coming to the Space City to accelerate their businesses thanks to a new program. Photo via nasa.gov

It's an Italian invasion in Houston — and it's happening in the name of accelerating innovation within aerospace.

For the first time, Italy has announced an international aerospace-focused program in the United States. The Italian Trade Agency and Italian Space Agency will partner with Space Foundation to launch Space It Up, an initiative that will accelerate six companies in Houston.

“The launch of Space It Up marks a pivotal moment in our ongoing commitment to nurturing innovation and facilitating global partnerships," Fabrizio Giustarini, Italian Trade Commissioner of Houston, says in a news release. "This program serves as a testament to the collaborative spirit that defines the aerospace industry. It represents the convergence of Italian ingenuity and Houston's esteemed legacy in space exploration, setting the stage for unprecedented advancements."

The Italian companies in the inaugural cohort represent various areas of cutting-edge aerospace innovations and technologies. The selected companies are:

  • Arca Dynamics, a space traffic management and Earth observation service provider.
  • Delta Space, a low-cost satellite connectivity for sensors and launch services.
  • Involve Space, a pseudo-satellite platform and intelligent software to enable access to space.
  • Nabu, an IoT and data analysis provider.
  • NOVAC, which is producing an innovative shapeable all-solid-state structural supercapacitor.
  • T4i, developing innovative engines to serve small satellite platforms.

ITA and Space Foundation will provide a six-week immersive program focused on the most important aspects of the aerospace industry that will also include business events, networking opportunities, and, ultimately, connect the Houston aerospace community with the Italian startups.

Space It Up will launch its kick-off event at noon on September 1 at Ion Houston, followed by a demo day on September 27. The Demo Day will demonstrate the transformative impact on the aerospace industry by presenting the progress on break-through technologies and projects like the acceleration programs.

The Houston office is one of five ITA offices in the U.S. Other partnerships include Houston-based digital platform leader Village Insights, which will serve as a digital epicenter for Italy’s aerospace companies.

“From the cradle of Renaissance to the frontiers of the cosmos, Italy’s heritage of space innovations knows no bounds,” Keli Kedis Ogborn, Space Foundation vice president of space and entrepreneurship, says in a news release. “With a legacy of scientific advancements, Italy continues to script a new chapter in history, this time with a broader focus on international collaboration and impactful growth to the evolving global space ecosystem.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”